Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?
Early detection, prognosis, and management of IgA nephropathy (IgAN) remain a challenge. Histological examination of renal tissue still comprises the only way to confirm an IgAN diagnosis. It is of great importance to establish noninvasive diagnostic, prognostic, and predictive biomarkers that would...
Main Authors: | Karolina Marek-Bukowiec, Andrzej Konieczny, Krzysztof Ratajczyk, Wojciech Witkiewicz |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | Disease Markers |
Online Access: | http://dx.doi.org/10.1155/2018/5205831 |
Similar Items
-
The Non-Coding RNA Landscape in IgA Nephropathy—Where Are We in 2021?
by: Izabella Z. A. Pawluczyk, et al.
Published: (2021-05-01) -
IgA in IgA nephropathy
by: Layward, Lorna
Published: (1992) -
P27 ROLE OF CORTICOSTEROID THERAPY IN IgA NEPHROPATHY - WHERE DO WE STAND?
by: S.P. Nagaraju, et al.
Published: (2016-11-01) -
IgA glycosylation in IgA nephropathy
by: Allen, Alice
Published: (1995) -
Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?
by: Hitoshi Suzuki, et al.
Published: (2016-01-01)